Top

Published in:

01-08-2015 | Original Research

Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice

Authors: Jennifer Doherty, Danielle C. Bonadies, Ellen T. Matloff

Published in: Journal of Genetic Counseling | Issue 4/2015

Abstract

Approaches to hereditary breast cancer testing are shifting as multi-gene panels become more widely available. This paper describes our center’s experience and outcomes of a 6-gene panel test as a first-tier approach in patients who were candidates for BRCA testing. Between July and December 2013, a 6-gene panel test was ordered for patients meeting criteria for BRCA testing. A retrospective review detailed the mutation and variant of uncertain significance (VUS) rates for the genes analyzed. The mutation rate was 5.2 % (n = 7) and the VUS rate was 6.7 % (n = 9). A subsequent review determined the number of BRCA-negative patients who would have been offered additional single gene testing had BRCA, only, been their first-tier test. Applying consensus criteria revealed 7.1 % (n = 9) cases that met criteria for additional testing. Pedigree analysis by a certified genetic counselor revealed 26.8 % (n = 34) cases that would have been offered additional testing based on personal and/or family history. Our results suggest that this panel may be warranted as a first-tier test for a small subset of patients, but likely represents over testing for the majority of patients who are candidates for BRCA testing. The genes selected for panels, the extra costs per patient and the chance of VUS must be considered before we uniformly switch from BRCA to full panel testing on all patients.

Ambry Genetics. (2014). BRCAplus: A 6-gene hereditary breast cancer test. White Paper. http://www.ambrygen.com/sites/default/files/pdfs/forms/most_updated/cancer/BRCAPlus_While %20_Paper_0214.pdf. Accessed on June 11, 2014.

Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., & Easton, D. F. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72(5), 1117–1130. doi:10.1086/375033.PubMedCentralPubMedCrossRef

Arpino, G., Bardou, V. J., Clark, G. M., & Elledge, R. M. (2004). Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Research, 6(3), R149–R156. doi:10.1186/bcr767.PubMedCentralPubMedCrossRef

Association for Molecular Pathology v. Myriad Genetics, Inc., et al. (2013). 12–398.

Benusiglio, P. R., Malka, D., Rouleau, E., De Pauw, A., Buecher, B., Nogues, C., & Caron, O. (2013). CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. Journal of Medical Genetics, 50(7), 486–489. doi:10.1136/jmedgenet-2012-101472.PubMedCrossRef

Chen, W.Y., & Colditz, G.A. (2006). Patient information: Tamoxifen and raloxifene for the prevention of breast cancer. 14.2:7.

Chompret, A., Brugieres, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., & Feunteun, J. (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer, 82(12), 1932–1937. doi:10.1054/bjoc.2000.1167.PubMedCentralPubMedCrossRef

Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., & National Comprehensive Cancer, N. (2010). Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network, 8(5), 562–594.PubMed

Daly, M., Axilbund, J., Buys, S., & Crawford, B. (2014). Genetics/familial high-risk assessment: Breast and Ovarian, Version 1.2014: National Comprehensive Cancer Network, Inc.

Fitzgerald, R. C., Hardwick, R., Huntsman, D., Carneiro, F., Guilford, P., Blair, V., & International Gastric Cancer Linkage, C. (2010). Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 47(7), 436–444. doi:10.1136/jmg.2009.074237.PubMedCentralPubMedCrossRef

Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., & Weitzel, J. N. (2009). Beyond li fraumeni syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology, 27(8), 1250–1256. doi:10.1200/JCO.2008.16.6959.PubMedCrossRef

Hearle, N., Schumacher, V., Menko, F. H., Olschwang, S., Boardman, L. A., Gille, J. J., & Houlston, R. S. (2006). Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clinical Cancer Research, 12(10), 3209–3215. doi:10.1158/1078-0432.CCR-06-0083.PubMedCrossRef

Hilbers, F. S. M., Vreeswijk, M. P. G., van Asperen, C. J., & Devilee, P. (2013). The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? Clinical Genetics, 84(5), 407–414. doi:10.1111/Cge.12256.PubMedCrossRef

Howlander, N. (2011). SEER cancer statistics review, 1975–2010. Bethesda: National Cancer Institute.

Kurian, A., Brugieres, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., Feunteun, J. (2014). Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. Epub ahead of print.

Masciari, S., Van den Abbeele, A. D., Diller, L. R., Rastarhuyeva, I., Yap, J., Schneider, K., & Garber, J. E. (2008). F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA, 299(11), 1315–1319. doi:10.1001/jama.299.11.1315.PubMedCrossRef

Mauer, C. B., Pirzadeh-Miller, S. M., Robinson, L. D., & Euhus, D. M. (2014). The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genetics in Medicine, 16(5), 407–412.PubMedCrossRef

Nelson, H.D., Fu, R., Griffin, J.C., Nygren, P., Smith, M.E., & Humphrey, L. (2009). Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med, 151(10), 703–715, W-226-735. doi: 10.7326/0003-4819-151-10-200911170-00147.

Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., Offit, K., & American Society of Clinical, O. (2010). American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901. doi:10.1200/JCO.2009.27.0660.PubMedCrossRef

Salmon, A., Amikam, D., Sodha, N., Davidson, S., Basel-Vanagaite, L., Eeles, R. A., & Peretz, T. (2007). Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clinical Oncology (Royal College of Radiologists), 19(7), 490–493. doi:10.1016/j.clon.2007.05.001.CrossRef

Schrader, K. A., Masciari, S., Boyd, N., Wiyrick, S., Kaurah, P., Senz, J., & Huntsman, D. G. (2008). Hereditary diffuse gastric cancer: association with lobular breast cancer. Familial Cancer, 7(1), 73–82. doi:10.1007/s10689-007-9172-6.PubMedCentralPubMedCrossRef

Tan, M. H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., & Eng, C. (2012). Lifetime cancer risks in individuals with germline PTEN mutations. Clinical Cancer Research, 18(2), 400–407. doi:10.1158/1078-0432.CCR-11-2283.PubMedCentralPubMedCrossRef

Title: Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice
Authors: Jennifer Doherty
Danielle C. Bonadies
Ellen T. Matloff
Publication date: 01-08-2015
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 4/2015
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-014-9796-2

At a glance: The STEP trials

Springer Medicine

Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Reduced Uptake of Family Screening in Genotype-Negative Versus Genotype-Positive Long QT Syndrome

Genetics Health Professionals’ Views on Quality of Genetic Counseling Service Provision for Presymptomatic Testing in Late-Onset Neurological Diseases in Portugal: Core Components, Specific Challenges and the Need for Assessment Tools

Perceptions of Latinas on the Traditional Prenatal Genetic Counseling Model

Genetic Counseling in Portugal: Education, Practice and a Developing Profession

Reporting Incidental Findings in Clinical Whole Exome Sequencing: Incorporation of the 2013 ACMG Recommendations into Current Practices of Genetic Counseling

Genetic Counselors’ and Genetic Counseling Students’ Attitudes Around the Clinical Doctorate and Other Advanced Educational Options for Genetic Counselors: A Report from the Genetic Counseling Advanced Degree Task Force